Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of preoperative radiotherapy plus pazopanib dose escalation in localized soft tissue sarcoma
NL-OMON39288Phase 1Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pazopanib in soft tissue sarcoma (STS), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and feasibility of adding pazopanib to preoperative radiotherapy, Dose-limiting toxicity and 1 more. Started Apr 2012; status: active, not recruiting.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON39288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39288.